
11 new spirits for the monsoon: Best tequilas, whiskeys and gins
The rains have arrived early this year — and with them, a sharp new crop of spirits. A legendary Nepali rum has entered the Indian market, there's a pink vodka that leans into fruit and florals, and homegrown distillers continue to push boundaries with aged malts and layered gins. From limited-edition whiskies to additive-free tequilas, here are some recent launches that have caught our attention.
Earlier this year, in an interview with this newspaper, Bacardi India MD Vinay Golikeri noted strong traction in the super-premium tequila segment. The Patron El Cielo — Bacardi owns Patron — sold out almost instantly, he said. A similar reception is likely for El Alto, which is set to launch later this week. Endorsed by Punjabi music star Karan Aujla, the luxury tequila is a blend of Extra Anejo, Anejo, and Reposado tequilas. El Alto, which will be priced at ₹29,500 in Mumbai, is made from 100% Blue Weber agave sourced from the Jalisco highlands and aged in a mix of American and French oak barrels. The result is a smooth, layered spirit with notes of cooked agave, vanilla, caramel, and ripe fruit — aimed squarely at the sipping tequila segment.
The tequila wave is not just about global giants. It is also drawing in Indian entrepreneurs such as Delhi-based Shivankar Bahl. The hospitality entrepreneur recently launched Las Maracas, a premium tequila, in Delhi with plans to expand to Mumbai, Goa, and Haryana. Produced in Jalisco, Mexico, in small batches without additives, Las Maracas is made from 100% Blue Weber agave and pure spring water. The range includes Blanco ( ₹5,300), Reposado ( ₹6,400), aged for four months in oak barrels, and Anejo ( ₹9,500), matured for 18 months to develop notes of vanilla and oak.
Revelry Distillery is a new craft-focused operation in Goa founded by beverage industry professional Vaniitha Jaiin. Its debut release, Vanaha Gin, is positioned as India's first gin to follow a five-step production process, combining copper pot distillation, vapour infusion, steeping, vacuum distillation, and post-distillation maceration. This layered approach, according to the company, allows the distillers to extract nuanced flavours from each of the 24 botanicals used, which include Deodar wood, patchouli, Assam lemon, wild berries, and cacao nibs. Vanaha is described as 'a complex gin with bright citrus top notes, warm spice mid-palate, and a slightly earthy, dry finish.' The gin is currently priced at ₹2,400 in Goa.
Amara, a pink vodka from Goa-based Spaceman Spirits Lab, also follows a five-step production method that includes a ruby filtration process. The vodka is made from Bangalore blue grapes and rice from the Deccan Plateau, and includes natural flavours such as strawberries, citrus, rose petals, and cherry blossom. The premium vodka is currently distributed across India by Tilaknagar Industries, which owns a stake in Spaceman Spirits Lab, reflecting a broader trend of larger alcobev companies investing in craft startups to diversify their portfolios and appeal to younger, premium-seeking consumers. The vodka, priced between ₹2,500 and ₹4,500, is available at select premium retail stores, high-end bars, and luxury hotels across Goa, Maharashtra, and Karnataka.
Piccadilly Distilleries has just released a limited edition 11-year-old single malt under its Indri label, matured in ex-Bordeaux red wine casks. Only 1,100 bottles are available globally. The whisky is bottled at 50% ABV for India and 58.5% ABV for international markets. It is described as a robust single malt with dark fruit aromas and a palate of spices, vanilla, and oak-derived sweetness.
The GlenJourneys Pioneer edition, launched by actor Ajay Devgn and spirits entrepreneur Moksh Sani, is another whisky worth keeping an eye out for if you are travelling. Limited to just 600 bottles, the 21-year-old whisky is aged in American oak casks and bottled at 48% ABV. The whisky is available through select international travel retain outlets. In August, the brand also plans to introduce a Cask Series, featuring non-age-statement expressions matured in rum, bourbon, and sherry casks, priced between ₹7,500 and ₹9,000.
Paul John Whisky has added two new expressions to its Select Cask range: the Port and the Madeira. Both are unpeated single malts, matured in ex-bourbon casks and finished in fortified wine casks sourced from Portugal. Each is bottled at 48% ABV. The use of fortified wine casks adds layered sweetness and complexity, and one can expect a burst of luscious flavours and aromas. These expressions are currently available in Goa ( ₹8000), Karnataka ( ₹7,700), and Maharashtra ( ₹18,000).
With sales of 1 million cases for two consecutive years (2022–23 and 2023–24), Radico Khaitan's Morpheus Brandy is a bonafide best-seller. Building on this success, the company recently launched the Morpheus Super Premium Whisky, blending imported Scotch malts with Indian grain spirits, matured in bourbon barrels, and bottled at 42.8% ABV. Priced between ₹1,200 and ₹1,500, this marks Radico's entry into the premium whisky segment.
If you've been to Nepal, chances are you've had some Khukri Rum. Launched in 1959 in Kathmandu by three Parsi businessmen, Khukri, named after the traditional curved dagger of the Gurkhas, is the country's most famous rum. About a month ago, Kathmandu-based MCKT Beverages introduced India to the rum, which is aged in Shorea robusta (sal wood) casks, an uncommon practice in rum production. The rum is available in Maharashtra, Uttar Pradesh, and Goa in three expressions: XXX, Spiced, and White. The Khukri Coronation, which comes in the iconic dagger-shaped bottle, is also being readied for launch. The XXX Rum is priced at ₹1,765, while the Spiced and White variants retail for ₹1,975 (Maharashtra).
A Danish non-alcoholic beverage made with a blend of up to 13 organic teas, Copenhagen Sparkling Tea is now available in India through Bebida Hospitality. The drink occupies a growing niche between wine and tea, and is positioned as a complex, celebratory option for those avoiding alcohol. Three blends have been introduced in India: Lyserod, a rosé-style with hibiscus and red berries; Lysegron, with citrus and green tea notes; and Bla, which features jasmine, chamomile, and Darjeeling First Flush. The launch comes at a time when interest in low- and no-alcohol beverages is rising, particularly among younger urban consumers exploring 'sober curious' lifestyles. Priced at ₹3,500, the sparkling teas are being stocked at luxury hotels and are also available for direct purchase online.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
42 minutes ago
- Business Standard
Ketan Kumar Joshi named J&K Bank CFO for 3-year term, replaces Fayaz Ganai
The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations Press Trust of India Srinagar The Jammu and Kashmir Bank on Sunday announced the appointment of Ketan Kumar Joshi as its new chief financial officer for a term of three years. Joshi has replaced Fayaz Ahmad Ganai, a spokesperson of the J&K Bank said. The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations. "A seasoned professional in banking and finance, Joshi brings over two decades of extensive experience across Indian and international financial institutions," the spokesperson said. Before joining the J&K Bank, Joshi served as CFO at North East Small Finance Bank Ltd. (2019-2024), where he successfully led a number of critical initiatives. He also spearheaded the bank's system migration from FIS (PROFILE) to BSG (TURING), ensuring capital growth aligned with business expansion and regulatory requirements. Joshi has served in Afghanistan with Maiwand Bank, Bakhtar Bank, and Ghazanfar Bank. He also served as senior vice president at Bank of Tokyo-Mitsubishi UFJ Ltd, Mumbai. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Time of India
44 minutes ago
- Time of India
Contribute to stable borders: Chinese President Xi urges residents of Tibetan village bordering Arunachal Pradesh
Beijing: Chinese President Xi Jinping on Sunday called on the Tibetan residents of a village situated near the Indian border to contribute towards fostering prosperity and stability in the border areas. "Learning that the village has undergone new changes in recent years and villagers' incomes have increased, I feel happy for you," Xi replied to a letter received from residents of Nyingchi, a prefecture-level area located close to the Arunachal Pradesh border. China claims Arunachal Pradesh as part of South Tibet, which is firmly rejected by India. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo Xi visited Nyingchi in 2021, becoming the only Chinese president to have visited the border areas of Tibet. Xi, in his letter, voiced hope that Nyingchi residents will, under the guidance of the Communist Party's policies to develop border areas and improve people's lives, do an even better job in protecting the natural beauty of the plateau region, developing the village's tourist brand, and contributing to building a prosperous and stable border area. Live Events In recent years, China has built a number of villages along the Tibetan border areas to ensure border security and development. In his letter, Xi also urged the people in the Tibet Autonomous Region to uphold ethnic solidarity and create a happier and better life, the state-run Xinhua news agency reported. During his 2021 visit to Nyingchi, Xi visited the Nyang River Bridge to inspect the ecological preservation in the basin of the Brahmaputra River , which is called Yarlung Zangbo in the Tibetan language. Last year, China approved the construction of the world's largest dam, stated to be the planet's biggest infrastructure project, costing USD 137 billion, on the Brahmaputra river in Tibet, which has raised concerns in the riparian states of India and Bangladesh.


Mint
an hour ago
- Mint
Torrent Pharma to acquire controlling stake in JB Chemicals from KKR
Ahmedabad-based drugmaker Torrent Pharmaceuticals is set to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR, at an equity valuation of ₹25,689 crore. The deal will be followed by a merger of the two entities, the company announced on Sunday evening. The deal will strengthen Torrent's presence in the Indian market, as well as facilitate its entry into the fast-growing contract development and manufacturing (CDMO) segment. Torrent will acquire a 46.39% equity stake (on a fully diluted basis) in JB Pharma through a share purchase agreement for ₹11,917 crore at ₹1,600 per share, followed by a mandatory open offer to acquire up to 26% of the company's shares from public shareholders, at an open offer price of ₹1,639.18 per share. Torrent also intends to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same share price as KKR, the company said in a release. The investment in JB Pharma yielded an over 5x return for KKR with a gross internal rate of return of about 36%, a person aware of the development, who did not wish to be quoted, told Mint. KKR has had a strong track record of healthcare investments in India, including a $600 million financing to Manipal Group recently and a 5x return on its investment in Max Healthcare in 2022. The acquisition will be followed by a merger between Torrent and JB Pharma through a scheme of arrangement. JB Pharma's shares rose 2.3% to ₹1,792.20 apiece, while those of Torrent Pharma settled 4.7% higher at ₹3,375 on the NSE on Friday. The acquisition will provide Torrent access to a fast-growing India franchise, with JB's leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology, strengthen Torrent's market share in the Indian market, and facilitate its entry into the CDMO segment. It will also aid consolidation in key international markets, the company said. 'Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint, offers immense potential to scale both revenue and profitability," Samir Mehta, executive chairman, Torrent Pharmaceuticals, said in the statement. 'Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent," he added. Torrent Pharma was engaged in prolonged talks to acquire KKR's stake in JB Pharma last year. The deal, however, fell through over valuation concerns. KKR acquired a 54% stake in JB Pharma from the promoters, the Mody family, in July 2020 for about ₹3,100 crore, or ₹745 per share. The investment firm sold over 5% of stake in the company in March 2025 through block deals for ₹1,459 crore, bringing its holding down to 47.84%. Torrent Pharmaceuticals has grown over the years through inorganic moves. In 2017, it acquired women's healthcare brands from Novartis, as well as Unichem's Indian branded business along with its Sikkim plant. In 2022, it acquired Curatio Healthcare for ₹2,000 crore. In an interview with the Economic Times earlier this month, Torrent's managing director-designate Aman Mehta said the company is aiming to be one of the top three pharma companies in the Indian market in the next three to five years. JB Pharma is one of the fastest growing pharma companies in India, and comes with flagship brands such as Cilacar, Metrogyl, Nicardia and Rantac. The company also exports its finished formulations to over 40 countries, including the US, and is a leading CDMO player in the segment of medicated lozenges. JB Pharma recorded revenue of ₹3,918 crore in FY24-25, growing 12% year-on-year. Of this, its revenue from the domestic market was ₹2,269 crore, growing 20% YoY. 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth as well as consistent improvement in profitability in the medium and long term," said Nikhil Chopra, chief executive officer and whole time director of JB Pharma.